...
首页> 外文期刊>The Australasian journal of dermatology >Accrual of non-melanoma skin cancer in renal-transplant recipients: Experience of a Victorian tertiary referral institution
【24h】

Accrual of non-melanoma skin cancer in renal-transplant recipients: Experience of a Victorian tertiary referral institution

机译:肾移植受者中非黑素瘤皮肤癌的累积:维多利亚州三级转诊机构的经验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Cutaneous carcinogenesis is increased in immunosuppressed organ transplant recipients (OTR). Tumour accrual is a useful measure for the rate of cutaneous carcinogenesis. There are few studies in tumour accrual rates in OTR in Australia. Methods This was a prospective study of renal transplant recipients in a single tertiary referral centre over 5 years (60 months). Outcome measures included tumour accrual, and numbers of skin cancers according to clinical risk factors (age, sex, anatomical location, skin phototype, duration of immunosuppression, history of graft rejection, acitretin use, occupational sun exposure and family history of skin cancer). Results A total of 142 patients were included in the study, with a median follow-up duration of 1.9 years. Of these patients, 53 (37%) developed a total of 341 invasive non-melanoma skin cancers (NMSC) (253 squamous cell carcinoma [SCC] and 88 basal cell carcinoma [BCC]) over the study period. Accrual for SCC and BCC were 0.89 SCC/patient per year and 0.31 BCC/patient per year, respectively. The overall NMSC accrual was 1.20 NMSC/patient per year. SCC accrual increased with the duration of immunosuppression. NMSC accrual increased with a history of graft rejection. Conclusions The current study provides prospective, histologically verified and quantitative evidence for the increase of cutaneous carcinogenesis in renal transplant recipients in Victoria, Australia.
机译:背景技术免疫抑制器官移植受者(OTR)的皮肤致癌作用增加。应计的肿瘤是皮肤癌发生率的有用量度。在澳大利亚,OTR中肿瘤累积率的研究很少。方法这是对单个三级转诊中心的肾移植受者进行的为期5年(60个月)的前瞻性研究。结果指标包括肿瘤的发生率和根据临床风险因素(年龄,性别,解剖位置,皮肤光型,免疫抑制时间,移植排斥史,阿维A使用,职业性日晒和皮肤家族病史)的皮肤癌数目。结果本研究共纳入142例患者,中位随访时间为1.9年。在这些患者中,有53名(37%)在研究期间共发展了341种浸润性非黑素瘤皮肤癌(NMSC)(253种鳞状细胞癌[SCC]和88种基底细胞癌[BCC])。 SCC和BCC的应计费用分别为0.89 SCC /每患者每年和0.31 BCC /每患者每年。每年的NMSC总数为1.20 NMSC /患者。随着免疫抑制持续时间的增加,SCC的累积增加。 NMSC的累积随着移植排斥的历史而增加。结论本研究为澳大利亚维多利亚州肾移植受者皮肤致癌作用增加提供了前瞻性,组织学验证和定量证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号